Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O.

Cancer Cell. 2019 Apr 15;35(4):705. doi: 10.1016/j.ccell.2019.03.012. No abstract available.

2.

Allogeneic hematopoietic cell transplantation in Farber disease.

Ehlert K, Levade T, Di Rocco M, Lanino E, Albert MH, Führer M, Jarisch A, Güngör T, Ayuk F, Vormoor J.

J Inherit Metab Dis. 2019 Mar;42(2):286-294. doi: 10.1002/jimd.12043. Epub 2019 Feb 27.

PMID:
30815900
3.

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.

Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE.

Haematologica. 2019 Sep;104(9):1804-1811. doi: 10.3324/haematol.2017.185975. Epub 2019 Jan 17.

4.

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Osborne C, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O.

Cancer Cell. 2018 Oct 8;34(4):626-642.e8. doi: 10.1016/j.ccell.2018.08.015. Erratum in: Cancer Cell. 2019 Apr 15;35(4):705.

5.

Epidemiology and biology of relapse after stem cell transplantation.

Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N.

Bone Marrow Transplant. 2018 Nov;53(11):1379-1389. doi: 10.1038/s41409-018-0171-z. Epub 2018 Apr 18. Review. No abstract available.

6.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

7.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

8.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
9.

Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G; Innovative Therapies for Children with Cancer (ITCC) Consortium.

Nat Rev Clin Oncol. 2017 Aug;14(8):497-507. doi: 10.1038/nrclinonc.2017.59. Epub 2017 May 16. Review.

PMID:
28508875
10.

Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.

Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, Dormon K, Pal D, Heidenreich O, Vormoor J.

Leukemia. 2017 Dec;31(12):2577-2586. doi: 10.1038/leu.2017.140. Epub 2017 May 10.

11.

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.

Duong JK, Griffin MJ, Hargrave D, Vormoor J, Edwards D, Boddy AV.

Br J Clin Pharmacol. 2017 Aug;83(8):1713-1722. doi: 10.1111/bcp.13260. Epub 2017 Mar 5.

12.

Dormancy Stems the Tide of Chemotherapy.

Pal D, Heidenreich O, Vormoor J.

Cancer Cell. 2016 Dec 12;30(6):825-826. doi: 10.1016/j.ccell.2016.11.014.

13.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26351. Epub 2016 Dec 1.

PMID:
27905678
14.

Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia.

Pal D, Blair HJ, Elder A, Dormon K, Rennie KJ, Coleman DJ, Weiland J, Rankin KS, Filby A, Heidenreich O, Vormoor J.

Leukemia. 2016 Aug;30(8):1691-700. doi: 10.1038/leu.2016.79. Epub 2016 May 25.

15.

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.

Weiland J, Pal D, Case M, Irving J, Ponthan F, Koschmieder S, Heidenreich O, von Stackelberg A, Eckert C, Vormoor J, Elder A.

Leukemia. 2016 Sep;30(9):1920-3. doi: 10.1038/leu.2016.64. Epub 2016 Mar 17. No abstract available.

16.

The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C.

Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11.

17.

The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J.

Leukemia. 2015 Aug;29(8):1623-31. doi: 10.1038/leu.2015.113. Epub 2015 May 6. Review.

PMID:
25943180
18.

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.

Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J.

Pediatr Blood Cancer. 2015 Jul;62(7):1144-8. doi: 10.1002/pbc.25462. Epub 2015 Mar 8. Review.

PMID:
25755168
19.

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.

Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C.

Blood. 2014 Nov 27;124(23):3420-30. doi: 10.1182/blood-2014-04-531871. Epub 2014 Sep 24.

20.

Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.

Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ, Bacon CM.

PLoS One. 2014 Jan 7;9(1):e85128. doi: 10.1371/journal.pone.0085128. eCollection 2014.

21.

Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.

Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O, Eder M.

Leukemia. 2014 Mar;28(3):554-65. doi: 10.1038/leu.2013.361. Epub 2013 Nov 27.

22.

The MLL recombinome of acute leukemias in 2013.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2013 Nov;27(11):2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30.

23.

Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations.

Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J.

EMBO Mol Med. 2013 Jan;5(1):38-51. doi: 10.1002/emmm.201201703. Epub 2012 Dec 11.

24.

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression.

Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, Bacon CM, Vormoor J, Heidenreich O.

Leukemia. 2013 Mar;27(3):718-21. doi: 10.1038/leu.2012.206. Epub 2012 Jul 18. No abstract available. Erratum in: Leukemia. 2013 Aug;27(8):1792.

25.

Leukaemia & cancer in neonates.

Vormoor J, Chintagumpala M.

Semin Fetal Neonatal Med. 2012 Aug;17(4):183-184. doi: 10.1016/j.siny.2012.04.001. Epub 2012 May 8. No abstract available.

PMID:
22572199
26.

Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia.

Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J.

Genes Chromosomes Cancer. 2012 Mar;51(3):250-6. doi: 10.1002/gcc.20949. Epub 2011 Nov 10.

PMID:
22072526
27.

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.

Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Starý J, Steinbach D, Vormoor J, Reinhardt D.

Leukemia. 2012 Apr;26(4):654-61. doi: 10.1038/leu.2011.267. Epub 2011 Oct 4.

PMID:
21968880
28.

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T.

Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.

29.

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

Gessner A, Thomas M, Castro PG, Büchler L, Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J, Heidenreich O.

Leukemia. 2010 Oct;24(10):1751-9. doi: 10.1038/leu.2010.155. Epub 2010 Aug 5.

PMID:
20686504
30.

Understanding the cancer stem cell.

Bomken S, Fiser K, Heidenreich O, Vormoor J.

Br J Cancer. 2010 Aug 10;103(4):439-45. doi: 10.1038/sj.bjc.6605821. Epub 2010 Jul 27. Review.

31.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.

PMID:
20220773
32.

Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.

Wilson K, Case M, Minto L, Bailey S, Bown N, Jesson J, Lawson S, Vormoor J, Irving J.

Haematologica. 2010 Apr;95(4):679-83. doi: 10.3324/haematol.2009.011726. Epub 2009 Nov 30.

33.

Malignant stem cells in childhood ALL: the debate continues!

Heidenreich O, Vormoor J.

Blood. 2009 Apr 30;113(18):4476-7; author reply 4477. doi: 10.1182/blood-2009-02-203109. No abstract available.

34.

A new subgroup of high-risk acute lymphoblastic leukaemia.

Vormoor J.

Lancet Oncol. 2009 Feb;10(2):101-3. doi: 10.1016/S1470-2045(09)70008-7. No abstract available.

PMID:
19185828
35.

Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002.

Feltbower RG, McNally RJ, Kinsey SE, Lewis IJ, Picton SV, Proctor SJ, Richards M, Shenton G, Skinner R, Stark DP, Vormoor J, Windebank KP, McKinney PA.

Eur J Cancer. 2009 Feb;45(3):420-7. doi: 10.1016/j.ejca.2008.09.020. Epub 2008 Nov 12.

PMID:
19004628
36.

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, Bailey S, Vormoor J, Hall AG, Irving JA.

Cancer Res. 2008 Aug 15;68(16):6803-9. doi: 10.1158/0008-5472.CAN-08-0101.

37.

In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J.

Cancer Cell. 2008 Jul 8;14(1):47-58. doi: 10.1016/j.ccr.2008.05.015.

38.

Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice.

Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, Gerke V, Hotfilder M, Vormoor J, Berdel WE, Serve H, Müller-Tidow C.

Cancer Res. 2008 Mar 15;68(6):1896-904. doi: 10.1158/0008-5472.CAN-07-2390.

39.

Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.

Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M.

Bone Marrow Transplant. 2007 Nov;40(10):945-9. Epub 2007 Sep 3.

PMID:
17768387
40.

Farber disease: clinical presentation, pathogenesis and a new approach to treatment.

Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J.

Pediatr Rheumatol Online J. 2007 Jun 29;5:15.

41.

Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.

Hempel G, Oechtering D, Lanvers-Kaminsky C, Klingebiel T, Vormoor J, Gruhn B, Boos J.

J Clin Oncol. 2007 May 1;25(13):1772-8.

PMID:
17470868
42.

Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach.

Ehlert K, Roth J, Frosch M, Fehse N, Zander N, Vormoor J.

Ann Rheum Dis. 2006 Dec;65(12):1665-6. No abstract available.

43.

Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.

Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, Schober O.

J Nucl Med. 2006 Oct;47(10):1635-42.

44.

Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination?

Florax A, Ehlert K, Becker K, Vormoor J, Groll AH.

Bone Marrow Transplant. 2006 Nov;38(9):639-40. Epub 2006 Sep 11. No abstract available.

PMID:
16964268
45.

Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.

Franzius C, Hotfilder M, Poremba C, Hermann S, Schäfers K, Gabbert HE, Jürgens H, Schober O, Schäfers M, Vormoor J.

Eur J Nucl Med Mol Imaging. 2006 Dec;33(12):1432-41. Epub 2006 Jul 29.

PMID:
16896672
46.

CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C.

Clin Exp Immunol. 2006 Jun;144(3):447-57.

47.
48.

Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).

Neudenberger J, Hotfilder M, Rosemann A, Langebrake C, Reinhardt D, Pieters R, Schrauder A, Schrappe M, Röttgers S, Harbott J, Vormoor J.

Br J Haematol. 2006 May;133(3):337-44.

PMID:
16643437
49.

PET/CT with diagnostic CT in the evaluation of childhood sarcoma.

Franzius C, Juergens KU, Vormoor J.

AJR Am J Roentgenol. 2006 Feb;186(2):581; author reply 581-2. No abstract available.

PMID:
16423975
50.

Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.

Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A.

J Clin Oncol. 2006 Jan 20;24(3):491-9.

PMID:
16421426

Supplemental Content

Loading ...
Support Center